Member Info for Thelix

The NHS can't afford most new medicines from the last decade. Sure we're all proud of hardworking nurses and doctors but the brutal reality is our equipment and machinery is still in the 20th century and our drugs list is ever dwindling. A lot of cancer treatments require people to go to America or Canada. NHS has had its day in my opinion. It seems good when you get treatment "free" but when you realise better detection and better treatments are widely available which you did not receive it does make you wonder.

is still beyond me. Glad it is finally on the move again. Only 3-4 days ago I said it would rise again and it seems to be going mental. Unfortunately has attracted some trader attention so we're seeing the usual P&D spikes. Still, longterm this will be double figures.

The MM's giveth and they taketh away. NASDAQ is where the money is, the movements prior bother me little as I am invested here rather than trading here.

has been massively overdone. It will return to higher figures. The external companies never said no to OXP and admitted their product would disrupt the market (make lots of money) but wanted to see further regulatory milestones reached. OXP is well funded and can spend the next 6 - 12 months getting that sorted.

If that cystic fibrosis trial is positive that will bounce the price a LOT

the profit train. Choo choo. Definitely primed for an excellent week next week.

When phase III is successful it will definitely be 30p+. But phase III wont be getting started until at least 12 months from now. I am confident this can easily go past 10p with little resistance and could press 20p within 12 months. It may indeed go higher - if the market gets excited about this company then it could do 30p, but I feel it would be shortlived until concrete phase III data comes through.

30p a share assuming no dilution/consolidation etc (which we shouldn't get much of in the near future) is a Mcap of £1 billion nearly. That might be quite optimistic, but upwards of 20p within the next 6-12 months is possible, in my personal opinion, DYOR etc. Not saying it WILL be 20p then, but has the potential to.

Due to currency wars etc, having a listing in Europe isn't great, and Germany is about to go down massively in certain sectors. Shall be fun times on the AIM/NASDAQ combo! Do a quick bit of research on other past AIM to NASDAQ listings - they spike massively, and tend to keep most of it.

Sellonnews has it correct. They will clump together ADR/ADS shares which will be worth multiple AIM shares. Other companies have done this with no consolidation at all

It's only a loss if you sell. This has had quite an over-reaction. Many companies said this WILL disrupt the market (that is good!) but they want more work done first (not even bad news!). If you buy a product do you want it half done, or mostly done. OXP simply need to get certain data, prove it in certain ways, get their regulation side sorted, audited, and many people will want to get involved. Pharma is a fickle business, people don't buy in lightly.

Agree completely. Once this gets on the NASDAQ, this should fly very high. I have seen pharmas bounce from AIM to NASDAQ - we are in for a very enjoyable and profitable ride! The only risk is failing phase IIb trials, and with our p values that is so unlikely this is almost guaranteed in the bag cash IMO. DYOR etc.

I am aware we're not on NASDAQ yet but you know, market sentiment, and all that jazz.

NASDAQ bio sector has taken a massive hit from the Clinton speeches mate. She wants companies to make brand new drugs within a few months, using a budget of £50 down the pub, and then keep interest rates at a flat 0.05%. Slight exxageration, but it has got a lot of pharma panicking and stock dropping. We are in a bearish summer market anyway..... At least there is one good part of Trump winning - the NASDAQ bio stocks should rise as he's happy with them making big profits.

Lots of cash and Nasdaq listing will see this easily double and triple todays price within weeks. The price barely moved from the 1st tranche, so not fussed at all. This isnt cash being raised for the directors bonus each year like other AIMs. This is cash to get through phase 2 and 3 and then springboard to commercialisation. Happy with the placements - theyre different to the usual AIM placements, which is why this hasnt moved down much with 100% dilution already.

From the way I understand it the shares being bought are the ones that have been added through a dilution process. Essentially it is a balancing act. These RNS's show who bought what quite a while ago and has now been put onto the market - they're not buys from the point of the RNS release, but prior. As a result these holdings are all going to be neutral players within the price movement - once more volume comes the price will go up. The NASDAQ will be the real money earner. Very much looking forward to that. Conservative estimate of 12-15p within 6 months of NASDAQ listing (so 12 months from now as ~180 days for NASDAQ listing). That's unless Hilary Clinton gets in - she wants Pharma to sell products at a loss and design new drugs out of the kindness of our hearts, so profit margins will jump off a cliff (for all pharma).

Not much to say really. This has been overdone. At no point did any company say this was junk. They liked the product and admitted it would disrupt the market, but first they wanted to see the company further its course before partnering. That is not bad news by any stretch. An annoying bump in the road but not a stop in the road. The company has a lot of cash and can work over the next 6-12 months to fulfill the requirements of what is needed

This has sweet FA to do with brexit. The companies said the work was good as are the products but some more work needs to be done before they partner. Short term downs but longterm ups IMO.

The companies admitted this would disrupt the OTC market (excellent news) but want to see more goal and scope of the compound. Wow what an overdone drop lol. The company needs to do some reg work and the other companies will be happy to partner with them. Good buy in price personally

Shooting back up again. People need to relax. Yes there is risk, any investment creates risk. But this is one of the best shares right now for risk/reward ratio. This will be 7p again in no time.